Trial | Mechanical thrombectomy cohort | IV r-tPA cohort | ||||||

Treatment | n | Age (±SD) | Median NIHSS (IQR) | Treatment | n | Age (±SD) | Median NIHSS (IQR) | |

MR CLEAN^{35} | ±IV r-tPA + MT ± (IA r-tPA or intra-arterial urokinase) | 233 | 65.8 (54.5–76)^{‡} | 17 (14–21) | ±IV r-tPA | 267 | 65.7 (55.5–76.4)^{‡} | 18 (14–22) |

REVASCAT^{36*} | ±IV r-tPA + M.T. | 103 | 65.7 (±11.3)^{¶} | 17 (14–20) | ±IV r-tPA | 103 | 67.2 (±9.5)^{¶} | 17 (12–19) |

EXTEND 1A^{37†} | IV r-tPA ± M.T. | 35 | 68.6 (±12.3)^{¶} | 17 (13–20) | IV r-tPA | 35 | 70.2 (±11.8)^{¶} | 13 (9–19) |

SWIFT-prime^{38†} | IV r-tPA ± M.T. | 98 | 65.0 (±12.5)^{¶} | 17 (13–20) | IV r-tPA | 98 | 66.3 (±11.3)^{¶} | 17 (13–19) |

ESCAPE^{39†} | M.T. ± IV r-tPA | 165 | 71 (60–81)^{‡} | 16 (13–20) | ±IV r-tPA | 150 | 70 (60–81)^{‡} | 17 (12–20) |

THRACE^{40†} | IV r-tPA ± M.T. | 200 | 66 (54–74)^{‡} | 18 (15–21) | IV r-tPA | 202 | 68 (54–75)^{‡} | 17 (13–20) |

THERAPY^{41*} | IV r-tPA ± M.T. | 55 | 67 (±11)^{¶} | 17 (13–22) | IV r-tPA | 53 | 70 (±10)^{¶} | 18 (14–22) |

PISTE^{42} | IV r-tPA ± M.T. | 33 | 67 (±17)^{¶} | 18 (6–24)^{§} | IV r-tPA | 32 | 64 (±16)^{¶} | 14 (6–29)^{§} |

EASI^{43*} | IV r-tPA ± M.T. | 40 | 74 (62.7–80)^{‡} | 18 (13–21.75) | IV r-tPA | 37 | 71 (59–79)^{‡} | 20 (12–23) |

*Enrolment was halted early after positive results for thrombectomy were reported from other similar trials.

†Trial stopped early due to efficacy.

‡Median (IQR).

§Median (±range).

¶Mean (±SD).

IV r-tPA , intravenous recombinant tissue-type plasminogen activator; IA r-tPA, intra-arterial recombinant tissue-type plasminogen activator; MT, mechanical thrombectomy; NIHSS , National Institutes of Health Stroke Scale; IQR, interquartile range; SD, standard deviation